Pharmaceuticals, Biotechnology and Life Sciences
First pharmaceutical cannabis factory was open in the USA on Tuesday, as Ultra Health, New Mexico’s first cannabis company with a nationwide presence, and Panaxia Pharmaceuticals Industries Ltd, an Israeli pharmaceutical company specializing in pharmaceutical cannabis R&D and manufacturing launched their facility in Bernalillo, New Mexico.
English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.
Swedish Orphan Biovitrum (Sobi) has received approval from the European Medicines Agency (EMA) for the grouped type II 15 K Variation for Elocta (efmoroctocog alfa), recombinant extended half-life factor VIII Fc fusion protein product for the treatment of haemophilia A.
Arix Bioscience and Takeda will work together to combine complementary skills and experience across important therapeutic areas in a strategic deal.
Biocartis Group has posted net income loss of €50.2 million for 2016, which is loss increase compared to last years €39.7 million net loss.
Eli Lilly’s senior vice president of global quality Fionnuala Walshis retiring after almost three decades at the company. Her replacement will be
PureTech Health has named Bharatt Chowrira as its President and Chief of Business and Strategyto work with the Chief Executive on strategy, corporate and business development, and value realisation across PureTech Health’s pipeline, the company said in its annoucement on Thursday.
Board of Directors has appointed its former executive vice preisdent Claus Bo Svendsen, as Chief Executive Officer, as it plans to pursue important objectives related to the the Settlement and License Agreement with Biogen.
Eli Lilly has completed acquisition of CoLucid Pharmaceuticals at a price of $46.50 per share through a second-step merger.
The U.S. Food and Drug Administration (FDA) approved Lexicon Pharmaceuticals’ Xermelo tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone couldn’t control properly.